Accounting for uncertainty in the historical response rate of the standard treatment in single‐arm two‐stage designs based on Bayesian power functions

In phase II single-arm studies, the response rate of the experimental treatment is typically compared with a fixed target value that should ideally represent the true response rate for the standard of care therapy. Generally, this target value is estimated through previous data, but the inherent variability in the historical response rate is not taken into account. In this paper, we present a Bayesian procedure to construct single-arm two-stage designs that allows to incorporate uncertainty in the response rate of the standard treatment. In both stages, the sample size determination criterion is based on the concepts of conditional and predictive Bayesian power functions. Different kinds of prior distributions, which play different roles in the designs, are introduced, and some guidelines for their elicitation are described. Finally, some numerical results about the performance of the designs are provided and a real data example is illustrated. Copyright © 2016 John Wiley & Sons, Ltd.

[1]  Chap T. Le.  Applied categorical data analysis and translational research , 2010 .

[2]  J. Bryant,et al.  Incorporating toxicity considerations into the design of two-stage phase II clinical trials. , 1995, Biometrics.

[3]  Sin-Ho Jung,et al.  Randomized phase II trials with a prospective control , 2008, Statistics in medicine.

[4]  D. Spiegelhalter,et al.  Bayesian Approaches to Clinical Trials and Health-Care Evaluation: Spiegelhalter/Clinical Trials and Health-Care Evaluation , 2004 .

[5]  Meinhard Kieser,et al.  Sample size planning for phase II trials based on success probabilities for phase III , 2015, Pharmaceutical statistics.

[6]  Stefania Gubbiotti.  Classical and Bayesian power functions; their use in clinical trials. , 2008 .

[7]  Valeria Sambucini.  A Bayesian predictive strategy for an adaptive two-stage design in phase II clinical trials. , 2010, Statistics in medicine.

[8]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[9]  Valeria Sambucini,et al.  A Bayesian predictive two‐stage design for phase II clinical trials , 2008, Statistics in medicine.

[10]  Fang Chen,et al.  Use of historical control data for assessing treatment effects in clinical trials , 2014, Pharmaceutical statistics.

[11]  W. Shih,et al.  A Bayesian–frequentist two‐stage single‐arm phase II clinical trial design , 2012, Statistics in medicine.

[12]  Ming Li,et al.  Bayesian designs with frequentist and Bayesian error rate considerations , 2005, Statistical methods in medical research.

[13]  Anastasios A Tsiatis,et al.  Adaptive two‐stage designs in phase II clinical trials , 2006, Statistics in medicine.

[14]  敏雄 下川.  Randomized Phase II Cancer Clinical Trials , 2015 .

[15]  Matteo Cellamare,et al.  A randomized two‐stage design for phase II clinical trials based on a Bayesian predictive approach , 2015, Statistics in medicine.

[16]  Pierpaolo Brutti,et al.  Robust Bayesian sample size determination in clinical trials , 2008, Statistics in medicine.

[17]  T. Chen,et al.  Optimal three-stage designs for phase II cancer clinical trials. , 1997, Statistics in medicine.

[18]  Sujit K. Sahu,et al.  A Bayesian method of sample size determination with practical applications , 2006 .

[19]  Weichung J Shih,et al.  Adaptive Two‐Stage Designs for Single‐Arm Phase IIA Cancer Clinical Trials , 2004, Biometrics.

[20]  David Machin,et al.  Bayesian two-stage designs for phase II clinical trials. , 2002, Statistics in medicine.

[21]  Fei Wang,et al.  A simulation-based approach to Bayesian sample size determination for performance under a given model and for separating models , 2002 .

[22]  Daniel J Sargent,et al.  Optimising the design of phase II oncology trials: the importance of randomisation. , 2009, European journal of cancer.

[23]  Ying Yuan,et al.  A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation , 2014, Statistics in medicine.

[24]  Morris L. Eaton,et al.  On the Limiting Behavior of the “Probability of Claiming Superiority” in a Bayesian Context , 2013 .

[25]  Fulvio De Santis.  Sample Size Determination for Robust Bayesian Analysis , 2006 .

[26]  Guosheng Yin,et al.  Clinical Trial Design: Bayesian and Frequentist Adaptive Methods , 2011 .

[27]  Hua Jin,et al.  A design of phase II cancer trials using total and complete response endpoints , 2005, Statistics in medicine.

[28]  C. Baey,et al.  Effect of a misspecification of response rates on type I and type II errors, in a phase II Simon design. , 2011, European journal of cancer.

[29]  D. Sargent,et al.  Randomized phase II trials: inevitable or inadvisable? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M R Conaway,et al.  Bivariate sequential designs for phase II trials. , 1995, Biometrics.

[31]  Manish R. Sharma,et al.  Randomized phase II trials: a long-term investment with promising returns. , 2011, Journal of the National Cancer Institute.

[32]  A. Zelenetz,et al.  Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  P F Thall,et al.  Practical Bayesian guidelines for phase IIB clinical trials. , 1994, Biometrics.